Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

C4 Therapeutics (CCCC) Interest & Investment Income (2020 - 2025)

Historic Interest & Investment Income for C4 Therapeutics (CCCC) over the last 6 years, with Q3 2025 value amounting to $2.2 million.

  • C4 Therapeutics' Interest & Investment Income fell 3722.75% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year decrease of 2321.43%. This contributed to the annual value of $14.4 million for FY2024, which is 4705.46% up from last year.
  • Per C4 Therapeutics' latest filing, its Interest & Investment Income stood at $2.2 million for Q3 2025, which was down 3722.75% from $2.5 million recorded in Q2 2025.
  • C4 Therapeutics' Interest & Investment Income's 5-year high stood at $3.9 million during Q1 2024, with a 5-year trough of $69000.0 in Q2 2021.
  • Moreover, its 5-year median value for Interest & Investment Income was $2.2 million (2023), whereas its average is $1.9 million.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first crashed by 7220.08% in 2021, then soared by 115661.76% in 2022.
  • Quarter analysis of 5 years shows C4 Therapeutics' Interest & Investment Income stood at $136000.0 in 2021, then surged by 1156.62% to $1.7 million in 2022, then skyrocketed by 72.62% to $2.9 million in 2023, then rose by 10.75% to $3.3 million in 2024, then plummeted by 31.25% to $2.2 million in 2025.
  • Its Interest & Investment Income was $2.2 million in Q3 2025, compared to $2.5 million in Q2 2025 and $2.8 million in Q1 2025.